Consistency of Safety and Efficacy of New Oral Anticoagulants across Subgroups of Patients with Atrial Fibrillation - Archive ouverte HAL Access content directly
Journal Articles PLoS ONE Year : 2014

Consistency of Safety and Efficacy of New Oral Anticoagulants across Subgroups of Patients with Atrial Fibrillation

(1) , , , , , , , ,
1
L. Bertoletti
  • Function : Author
C. Gremillet
  • Function : Author
C. Chapelle
  • Function : Author
P. Mismetti
  • Function : Author
M. Cucherat
  • Function : Author
D. Vital-Durand
  • Function : Author
S. Laporte
  • Function : Author
Behalf of The Meta-Embol Group
  • Function : Author

Abstract

Aims: The well-known limitations of vitamin K antagonists (VKA) led to development of new oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta-analysis was to determine the consistency of treatment effects of NOAC irrespective of age, comorbidities, or prior VKA exposure. Methods and Results: All randomized, controlled phase III trials comparing NOAC to VKA up to October 2012 were eligible provided their results (stroke/systemic embolism (SSE) and major bleeding (MB)) were reported according to age (<= or >75 years), renal function, CHADS2 score, presence of diabetes mellitus or heart failure, prior VKA use or previous cerebrovascular events. Interactions were considered significant at p<0.05. Three studies (50,578 patients) were included, respectively evaluating apixaban, rivaroxaban, and dabigatran versus warfarin. A trend towards interaction with heart failure (p = 0.08) was observed with respect to SSE reduction, this being greater in patients not presenting heart failure (RR = 0.76 [0.67-0.86]) than in those with heart failure (RR = 0.90 [0.78-1.04]); Significant interaction (p = 0.01) with CHADS2 score was observed, NOAC achieving a greater reduction in bleeding risk in patients with a score of 0-1 (RR 0.67 CI 0.57-0.79) than in those with a score >= 2 (RR 0.85 CI 0.74-0.98). Comparison of MB in patients with (RR 0.97 CI 0.79-1.18) and without (RR 0.76 CI 0.65-0.88) diabetes mellitus showed a similar trend (p = 0.06). No other interactions were found. All subgroups derived benefit from NOA in terms of SSE or MB reduction. Conclusions: NOAC appeared to be more effective and safer than VKA in reducing SSE or MB irrespective of patient comorbidities. Thromboembolism risk, evaluated by CHADS2 score and, to a lesser extent, diabetes mellitus modified the treatment effects of NOAC without complete loss of benefit with respect to MB reduction.

Dates and versions

hal-02046823 , version 1 (22-02-2019)

Identifiers

Cite

Jean-Christophe Lega, L. Bertoletti, C. Gremillet, C. Chapelle, P. Mismetti, et al.. Consistency of Safety and Efficacy of New Oral Anticoagulants across Subgroups of Patients with Atrial Fibrillation. PLoS ONE, 2014, 9 (3), pp.e91398. ⟨10.1371/journal.pone.0091398⟩. ⟨hal-02046823⟩
14 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More